Enhancing innate immunity through gut microbiome-derived polysaccharide A

Design Brief

Keerti Daesety and Aaron Mistry

BioBuilderClub, Andover High School, Andover, MA, USA

Reviewed on 8 May 2021; Accepted on 28 June 2021; Published on 25 October 2021
With help from the 2021 BioTreks Production Team.

AbstractBadgesVideoPDFCopyright
The human body harbors a vast  array of microorganisms such as bacteria, fungi, viruses, and other microbes collectively called the human microbiome. Diseases such as inflammatory bowel disease, rheumatoid arthritis, and immunodeficiency were all linked to dysregulated interaction between microbiome and host . Gut bacteria interact with cells in the intestine through the intestinal mucous layer, which is facilitated by polysaccharides produced by the bacteria. Past efforts to alter the intestinal immune response through a mix of commensal bacteria, probiotics, genetically engineered bacteria, or metabolites have not resulted in significant therapeutic benefits. Thus, we propose orally administering ingestible vesicles loaded with a known effector molecule, polysaccharide A (PSA).  PSA produced by Bacteroides fragilis, a common gut bacteria, is shown to prevent intestinal inflammation in animal models. We propose to overexpress the gene responsible for producing PSA, produce the polysaccharide in vitro, and package it into vesicles for testing in mice. This approach is expected to increase the efficacy of PSA as the vesicles can fuse to intestinal mucosa and anchor the PSA for prolonged exposure. We expect this product to increase the human innate immune response through its secretion of crucial immunity mediating cells that act as the first defense against pathogens (Montalban-Arques 2018). We will assess the treatment effect on key intestinal innate immunity mediating cells such as intraepithelial lymphocytes and innate lymphoid cells. Once proven in mice, the same therapeutic approach can be adopted to humans to cure immune diseases or to enhance overall innate immunity.

Keywords: Innate immunity, microbiota, immunity, polysaccharide A, Bacteroides fragilis

Authors are listed in alphabetical order. Lindsey L’Ecuyer mentored the group. Please direct all correspondence to llecuyer@k12.andoverma.us.

This is an Open Access article, which was copyrighted by the authors and published by BioTreks in 2021. It is distributed under the terms of the Creative Commons Attribution License, which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background 

Bacteria, fungi, viruses, and other microorganisms that live on and inside the human body, collectively known as the human microbiome,are the largest invisible organs of the human body.  In fact, there are more microbial cells in the human body than human cells. It is estimated that 10-100 trillion bacteria of the total microbiota primarily live in the gut (Ursell et al., 2012). Research over the last decade has shown the key role these gut bacteria play in the health and disease of the hosting individual (Jiao et al., 2020). Autoimmune diseases such as rheumatoid arthritis and spondyloarthritis  were all linked to the dysregulated microbiome and host interaction (Jiao et al., 2020). 

Gut bacteria interact with intestinal cells through the intestinal mucous layer which is facilitated by molecules known as polysaccharides secreted by the gut bacteria. Although the human intestinal microbiota has more than 2172 bacterial species, Bacteroides fragilis is an important member of the gut microbiota that protects animals from experimentally induced colitis  (Masmanian et al., 2008).  This beneficial activity requires the immunomodulatory molecule PSA as B. fragilis largely depends on its highly complex and dynamic capsular PSA for its symbiotic interactions with the host. PSA is a zwitterionic polysaccharide that is made of repeating tetrasaccharide units each consisting of a positively charged amino group and a negatively charged carboxylate group (Ertuk-Hasdemir et al., 2019).

Bacterial capsules are extracellular structures typically composed of polysaccharides that are located outside the cell envelope. Most bacterial capsular polysaccharides are not zwitterionic thus making PSA very unique.

Past studies using murine models have demonstrated that B. fragilis and its produced PSA are effective in inhibiting colitis and experimental allergic encephalomyelitis (Wu & Wu, 2012). PSA induces regulatory T cells secreting the anti-inflammatory cytokine IL-10, which prevents pathogenic inflammation in the gut (Ramakrishna et al., 2019). PSA from B. fragilis was reported to protect against colorectal cancer (CRC) via TLR2 signaling as the immunomodulator inhibited CRC cell proliferation by controlling the cell cycle and impeding CRC cell migration and invasion (Sittipo et al., 2018). PSA was also shown to direct the maturation of the developing immune system in mice, including correction of systemic T cell deficiencies and Th1/Th2 imbalances in lymphoid tissues (Zheng et al., 2020). 

Systems Level

We propose testing orally ingestible vesicle suspensions loaded with the immunomodulatory molecule PSA. By using a suspension, PSA’s molecular structure is preserved avoiding further degradation as compared to a capsule or tablet in which excipients are generally added which could act to lower PSA potency. This approach aims to increase the efficacy of the molecule as the vesicles can fuse to the intestinal mucosa and anchor the PSA for prolonged exposure. A longer PSA exposure is expected to elicit the beneficial effects of the bacteria by inducing intraepithelial lymphocytes and innate lymphoid cells without the bacteria (Figure 1). PSA treatment that fuses through its vesicle is also expected to avoid a host immune reaction when the bacteria is present as a whole organism (Figure 1). Additionally, by using PSA vesicles, degradation in the stomach is avoided. Vesicles are expected to survive stomach acid as stomach acid mostly acts on  water-soluble structures rather than the oily PSA vesicle.

Figure 1. This construct is the proposed mechanism of action for the PSA vesicles. The engineered vesicle contains PSA which will induce the production of intraepithelial lymphocytes and innate lymphoid cells.

Device Level 

Using the Wzx/Wzy-dependent assembly pathway known to synthesize bacterial polysaccharides, the genes Wzx flippase, Wzy polymerase, and Wzz chain-length regulator proteins will be excised and loaded onto a plasmid (Zeidan et al., 2017). Adding this plasmid to the bacterial culture will then be assessed to determine if the culture can successfully digest lactose (Figure 2). 

Figure 2. Inducing overexpression of PSA in B. fragilis. This construct is composed of four genetic parts, further explained in the parts level.

Parts Level

Our proposed system will utilize the B. fragilis strain NCTC9343 (Microbiologics, 2021). PSA in B. fragilis will be overexpressed by the Wzx/Wzy-dependent assembly pathway which contains the genes Wzx flippase, Wzy polymerase, and Wzz chain-length regulator proteins (Islam & Lam, 2014). We propose excising the Wzx/Wzy-dependent assembly pathway from the B. fragilis genome using PCR and restriction endonucleases. Then, we will also load the Wzx, Wzy, and Wzz genes onto a plasmid containing the lac operon and appropriate restriction endonucleases and ligases such as EcoRV and DNA ligase. This engineered plasmid will then be added to the overnight B. fragilis culture which does not have the ability to digest lactose (Parker & Smith, 2012) (Figure 2). Properly transformed B. fragilis will have the ability to metabolize lactose. Successfully transformed bacteria will be isolated on agar plates using the chemical compound X-gal, which will turn the bacteria blue if the lac operon is functional. The transformed cells can therefore overexpress the stronger and inducible lac operon promoter coupled Wzx/Wzy-dependent pathway when lactose is present in the growth media which will then lead to excess PSA production.

PSA overexpressing bacteria will be grown in a fermenter in brain heart infusion (BHI) broth. Bacterial pellets will be harvested, and soluble material will be isolated by phenol/chloroform extraction. Nucleic acids and proteins will be digested with DNase/RNase and Pronase K, respectively. PSA will be purified using column chromatography. The purified PSA will be dissolved in phosphate- buffered saline (PBS) to obtain a stock solution of 1 mg/mL. Phosphate-buffered saline (PBS) will be used as a control treatment for this study. The molecular structure of PSA will be confirmed by Nuclear Magnetic Resonance (NMR) analysis. Pure PSA will be encapsulated into lipid vesicles. 

Safety

 Lipid vesicle suspensions containing PSA or a phosphate-buffered saline (PBS) placebo will be administered orally in mice for 8 weeks. Animals will be sacrificed after 8 weeks, and intestinal cells will be harvested and analyzed for intraepithelial lymphocytes and innate lymphoid cells. Intraepithelial lymphocytes and innate lymphoid cells will be isolated and characterized through their markers, and induction will be measured by flow cytometry. PSA-treated cells are expected to have a higher number of lymphocytes and lymphoid cells which in turn should enhance innate immunity. We will also assess IL-10 gene induction and protein levels – the IL-10 gene prevents pathogenic inflammation in the gut (Ramakrishna et al., 2019). Induction of IL-10 will be analyzed by real-time PCR (qPCR) with primers specific to cDNA of IL-10. Intestinal cell IL-10 levels will be assessed by the IL-10 ELISA kit. IL-10 gene and protein levels are expected to increase in animal-treated cells conferring anti-inflammatory effects.

The methods used are all BSL-2 standard lab procedures and standard aseptic safety protocols will be followed for all experiments.  All live bacteria will be autoclaved prior to dispensing.  More importantly, B. fragilis is a commensal bacterium in the human colon and is not pathogenic. PSA produced by B. fragilis is a naturally occurring polysaccharide with no known toxicity. There are no known hazardous chemicals or pathogenic biologic drugs administered to mice.  

Discussions

The discovery of microbiome-host interactions within the last decade presents an opportunity to address various immune diseases and raise innate immunity in general. The field of synthetic biology enables us to utilize the principles of molecular biology and metabolic engineering to design biological circuits that can beneficially influence the host response. Our approach eliminates the need to use whole bacteria, genetically engineered bacteria, or even bacterial metabolites. Using a naturally occurring molecule in a lipid vesicle suspension is a key advantage of this approach. Once proven effective in mice, the same therapeutic approach can be adopted to humans to cure immune diseases or to enhance overall innate immunity.

Next Steps  

With the completion of our background research, we would need to run a variety of tests to determine if our selected Wzx/Wzy-dependent assembly pathway will be effective to increase PSA production.  After further testing is completed and confirms this approach will work, it could be developed into the therapeutic we hope to create.  

In a high school environment, we recognize that there are evident limitations in regards to how far we can investigate. Although we may not be able to conduct advanced experimentation, we hope that, with the help of our mentors, we could find resources to help further our research. By using concept experimentation and the equipment that we can access, we hope to be able to integrate our ideas into real life to help alleviate and provide a cure for immune diseases. 

Author Contributions

K.D. took the lead in creating the diagrams and centering the project’s focus on the immunomodulatory molecule PSA.   A.M. contributed to researching and providing feedback. A.M. also provided a critical role in the revising and citations process.

Acknowledgements

We would like to thank the BioBuilders Organization and our teacher and leader of the Andover High School BioBuilders Club, Mrs. L’Ecuyer for kindly providing her feedback, support, and encouragement through the duration of our project. 

This project was accomplished through participation in the BioBuilderClub, an after-school program organized by BioBuilder Educational Foundation.BioBuilderClub engages high school teams around the world to combine engineering approaches and scientific know-how to design/build/test their own project ideas using synthetic biology.  

References 

Bacteroides fragilis derived from NCTC 9343. (n.d.). Retrieved from https://www.microbiologics.com/0358K

Bacteroides fragilis polysaccharide A (PSA); IL-10; IL-17. (2008). Science-Business eXchange 1, 473. https://doi.org/10.1038/scibx.2008.473

Ertuk-Hasdemir, D., Oh, S. F., Okan, N. A., Stefanetti, G., Gazzaniga, F. S., Seeberger, P. H., Plevy, S. E., & Kasper, D. L. (2019, December). Symbionts exploit complex signaling to educate the immune system. Proceedings of the National Academy of Sciences of the United States of America, 116(52), 26157-26166. https://doi.org/10.1073/pnas.1915978116

Islam, S. T., & Lam, J. S. (2014). Synthesis of bacterial polysaccharides via the Wzx/Wzy-dependent pathway. Canadian Journal of Microbiology, 60(11), 697-716. https://doi.org/10.1139/cjm-2014-0595

Jiao, Y., Wu, L., Huntington, N. D., & Zhang, X. (2020). Crosstalk between gut microbiota and innate immunity and its implication in autoimmune diseases. Frontiers in Immunology, 11(282). https://doi.org/10.3389/fimmu.2020.00282

Mazmanian, S. K., Round, J. L., & Kasper, D. L. (2008). A microbial symbiosis factor prevents intestinal inflammatory disease. Nature, 453(7195), 620-625. https://doi.org/10.1038/nature07008

Montalban-Arques, A., Chaparro, M., Gisbert, J. P., & Bernardo, D. (2018). The innate immune system in the gastrointestinal tract: Role of intraepithelial lymphocytes and lamina propria innate lymphoid cells in intestinal inflammation. Inflammatory Bowel Diseases, 24(8), 1649-1659. https://doi.org/10.1093/ibd/izy177

Parker, A. C., & Smith, C. J. (2012). Development of an IPTG inducible expression vector adapted for Bacteroides fragilis. Plasmid, 68(2), 86-92. https://doi.org/10.1016/j.plasmid.2012.03.002

Ramakrishna, C., Kujawski, M., Chu, H., Li, L., Mazmanian, S. K., & Cantin, E. M. (2019). Bacteroides fragilis polysaccharide A induces IL-10 secreting B and T cells that prevent viral encephalitis. Nature Communications, 10(1), 1-13. https://doi.org/10.1038/s41467-019-09884-6

Sittipo, P., Lobionda, S., Choi, K., Sari, I. N., Kwon, H. Y., & Lee, Y. K. (2018). Toll-like receptor 2-mediated suppression of colorectal cancer pathogenesis by polysaccharide A from Bacteroides fragilis. Frontiers in Microbiology, 9, 1588. https://doi.org/10.3389/fmicb.2018.01588

Ursell, L. K., Metcalf, J. L., Parfrey, L. W., & Knight, R. (2012). Defining the human microbiome. Nutrition Reviews, 70(suppl_1), S38-S44. https://doi.org/10.1111/j.1753-4887.2012.00493.x

Wu, H. J., & Wu, E. (2012). The role of gut microbiota in immune homeostasis and autoimmunity. Gut Microbes, 3(1), 4-14. https://doi.org/10.4161/gmic.19320

Zeidan, A. A., Poulsen, V. K., Janzen, T., Buldo, P., Derkx, P. M., Øregaard, G., & Neves, A. R. (2017). Polysaccharide production by lactic acid bacteria: From genes to industrial applications. FEMS Microbiology Reviews, 41(Supp_1), S168-S200. https://doi.org/10.1093/femsre/fux017

Zheng, D., Liwinski, T., & Elinav, E. (2020). Interaction between microbiota and immunity in health and disease. Cell Research, 30(6), 492-506. . https://doi.org/10.1038/s41422-020-0332-7